Pricing models must evolve in tandem with drug innovation, according to an article published on eyeforpharma.
However, in a “cash-strapped healthcare system,” the difficulty in developing and implementing innovative payment models is a “mountainous challenge.”
Numerous companies are reportedly taking up the challenge, though.
Roche, according to the article, has made efforts to support payers by offering “flexible pricing solutions,” Roche’s Esther Haik said.
“We want to reassure payers that they will only pay for the benefit that treatment delivers for the right patients — those that respond,” she said.